NCT01577654 - Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer | Biotech Hunter

Enrollment

203

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

August 31, 2015

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

EC145

2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks)

DRUG

EC145 + Docetaxel

"EC145 2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks) +~Docetaxel 75 mg/m2 IV Day 1 q 3 weeks"

DRUG

Docetaxel

75 mg/m2 IV Day 1 q 3 weeks

DRUG

EC20

During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging